Abstract Body

Due to its low CNS penetrance, there are concerns about the capacity of non-conventional ART to preserve neurocognitive performance (NP).

The SALT study is a multicentre, open-label, non-inferiority clinical trial that compares whether 3TC+ATV/r (dual therapy; DT) is non-inferior to 2NRTI+ATV/r (triple therapy; TT), in HIV+ patients on a stable 3-drug regimen. The SALT NP sub-study (per protocol analysis) was performed to evaluate the effects over NP of DT vs. standard TT. A global deficit score (GDS) of 5 neurocognitive tasks selected following AAN-2007 criteria were used to assess NP at baseline (BL), W48 and W96. Changes in the neurocognitive impairment rates (NI) (GDS >0.5) and NP (GDS value) were determined at W48 and W96. The effect of DT over GDS at W96 adjusted by GDS at BL, GDS at W48 and significant confounders that change the relation between DT and GDS at W96 >20% was determined using ANCOVA.

Per protocol analysis included 92 participants (DT: 47 vs. TT 45). All BL characteristics were comparable in both groups, including mean [95% CI] GDS change: DT 1.2 [0.9 – 1.5] vs. TT 1.1 [0.8 – 1.5]; p=0.80) and rate of NI (DT 66% vs. TT 62.2%; 0.71). At W48 and W96, GDS changes (W48: DT -0.3 [-0.5 to -0.1] vs. TT -0,2 [-0.4 to 0.0]; p=0.39. W96: DT -0.3 [-0.5 to -0.1] vs. TT -0.2 [-0.4 to -0.1]; p=0.471) and rates of NI (W48: DT 55.3% vs. TT 51.1; p=0.69. W96: DT 51.1% vs. TT 51.1%; p=0.99) were similar. This absence of differences was also observed in all cognitive tasks. At W96, two participants in each group developed NI (incidence rate: DT 12.5% vs. TT 11.8%; p=0.95). DT use did not impact NP change: GDS at W96 adjusted by BL and W48 GDS and significant confounders (none) was -0.26 [-0.39 to -0.12] on DT vs. -0.27 [-0.41 to – 0.13] on TT (p=0.90).

Neucognitive performance remained stable after 96 weeks both in ATV/r+3TC arm as in the 2NRTI+ATV/r arm provided HIV-suppression was maintained. In this trial, ATV/r + 3TC showed a safe neurocognitive profile through 96 weeks.